tetano
Editor, Senior Moderator
Arch Pharm (Weinheim)
. 2022 Jan 17;e2100382.
doi: 10.1002/ardp.202100382. Online ahead of print.
A comprehensive update on the structure and synthesis of potential drug targets for combating the coronavirus pandemic caused by SARS-CoV-2
Prerna Malik[SUP] 1 [/SUP], Sonika Jain[SUP] 1 [/SUP], Pankaj Jain[SUP] 2 [/SUP], Jyoti Kumawat[SUP] 1 [/SUP], Jaya Dwivedi[SUP] 1 [/SUP], Dharma Kishore[SUP] 1 [/SUP]
Affiliations
Abstract
The outbreak of the coronavirus pandemic COVID-19 created by its severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) variant, known for producing a very severe acute respiratory syndrome, has created an unprecedented situation by its continual assault around the world. The crisis caused by the SARS-CoV-2 variant has been a global challenge, calling to mitigate this unprecedented pandemic that has engulfed the whole world. Since the outbreak and spread of COVID-19, many researchers globally have been grappling to find new clinically trialed active drugs with anti-COVID-19 activity, from antimalarial drugs to JAK inhibitors, antiviral drugs, immune suppressants, and so forth. This article presents a brief discussion on the activity and synthesis of some active molecules such as favipiravir, hydroxychloroquine, pirfenidone, remdesivir, lopinavir, camostat, chloroquine, baricitinib, molnupiravir, and so forth, which are under trial.
Keywords: COVID-19 pandemic; Delta+ variant; SARS-CoV-2 variant; lopinavir; remdesivir.
. 2022 Jan 17;e2100382.
doi: 10.1002/ardp.202100382. Online ahead of print.
A comprehensive update on the structure and synthesis of potential drug targets for combating the coronavirus pandemic caused by SARS-CoV-2
Prerna Malik[SUP] 1 [/SUP], Sonika Jain[SUP] 1 [/SUP], Pankaj Jain[SUP] 2 [/SUP], Jyoti Kumawat[SUP] 1 [/SUP], Jaya Dwivedi[SUP] 1 [/SUP], Dharma Kishore[SUP] 1 [/SUP]
Affiliations
- PMID: 35040187
- DOI: 10.1002/ardp.202100382
Abstract
The outbreak of the coronavirus pandemic COVID-19 created by its severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) variant, known for producing a very severe acute respiratory syndrome, has created an unprecedented situation by its continual assault around the world. The crisis caused by the SARS-CoV-2 variant has been a global challenge, calling to mitigate this unprecedented pandemic that has engulfed the whole world. Since the outbreak and spread of COVID-19, many researchers globally have been grappling to find new clinically trialed active drugs with anti-COVID-19 activity, from antimalarial drugs to JAK inhibitors, antiviral drugs, immune suppressants, and so forth. This article presents a brief discussion on the activity and synthesis of some active molecules such as favipiravir, hydroxychloroquine, pirfenidone, remdesivir, lopinavir, camostat, chloroquine, baricitinib, molnupiravir, and so forth, which are under trial.
Keywords: COVID-19 pandemic; Delta+ variant; SARS-CoV-2 variant; lopinavir; remdesivir.